Since late July, statutory health insurance no longer covers cannabis flowers. Patients with prior approvals face legal uncertainty, and social courts are answering differently. Four emergency rulings, two opposing lines of reasoning.
📑 Inhaltsverzeichnis
With the GKV Contribution Rate Stabilization Act, dried cannabis flowers fell out of the special performance claim under Section 31, Subsection 6 of the Social Code (SGB V) at the end of July 2026. For new applications, the situation is clear. What remains uncertain is what happens to existing approvals that health insurers had granted beforehand. Patients took their cases to social courts, and the outcomes have depended on jurisdiction.
The Line Protecting Existing Approvals
The Dresden Social Court ruled in emergency proceedings (case number S 11 KR 486/26 ER) that a granted approval can still create a claim for continued provisional supply even after the law change took effect. If the approval explicitly covers cannabis flowers, it requires a formal revocation notice from the insurance company under this interpretation. The law change alone is insufficient. The court ordered the insurer to continue provisional coverage.
The Landshut Social Court followed the same logic (case number S 16 KR 271/26 ER). There, the central question was whether an objection to revoking an approval has suspensory effect. The court affirmed this, meaning the revocation was temporarily halted.
The shared principle behind both decisions: an approval is an administrative act, and an administrative act doesn’t disappear simply because its legal basis changes. It must be formally revoked, and revocations can be challenged through legal remedies.
The Line Rejecting Protection
The Frankfurt am Main Social Court rejected an emergency petition (case number S 14 KR 409/26 ER). According to its ruling, no entitlement to cannabis flower coverage exists as of July 30, 2026. Without a statutory basis for the claim, the reasoning goes, even a prior approval cannot sustain entitlement.
The Leipzig Social Court reached the same conclusion. We already analyzed this decision when it became public in late September. It was the first published answer to this question at the time, and it ruled against patients.
What This Means in Practice
Three points matter before reading too much into these rulings.
First, these are all emergency proceedings. They decide only provisional arrangements, not the claim conclusively. Second, these are individual case decisions without final legal force; insurers can appeal. Third, the specific wording of each approval clearly matters. The Dresden decision specifically relies on whether the approval explicitly names cannabis flowers.
Affected patients shouldn’t conclude from press reports that their case is settled. Instead, they should review their own insurance approval document and seek legal counsel if uncertain. A ruling from a higher court remains pending.
A Legal Opinion and a Second Problem
The legal discrepancy has now been analyzed in detail. A legal opinion by Judith Heimbürger, reported by Legal Tribune Online, examines the consequences of the reimbursement restriction and contextualizes the contradictory rulings.
In parallel, a second dispute affects these same patients: the Association of Statutory Health Insurance Physicians and the GKV umbrella organization disagree over prescription requirements in off-label use, prompting parliamentary factions to pursue legislative amendments. Combined with efforts to relax the finished pharmaceutical priority—which we reported on—a picture emerges of regulations requiring multiple post-enactment adjustments. We’ve compiled the figures the federal government attributes to the priority itself.
For affected patients, this is not academic debate. Our analysis of what one milligram of THC costs depending on supply source shows the financial stakes. Patient representatives on the Joint Federal Committee had called for grandfathering protections, and the Working Group Cannabis as Medicine attempted to achieve it through a parliamentary petition.
Sources: Social court rulings from Dresden (S 11 KR 486/26 ER), Landshut (S 16 KR 271/26 ER), and Frankfurt am Main (S 14 KR 409/26 ER), published via sozialgerichtsbarkeit.de; Legal Tribune Online reporting on Judith Heimbürger’s legal opinion; Cannabis industry association newsletter dated October 21, 2026; our own reporting. Status: October 21, 2026. This article does not constitute legal advice.
Sollten Altgenehmigungen für Cannabisblüten weiter gelten?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
